Roche’s cobas SARS-CoV-2 Test Receives the US FDA’s Emergency Use Authorization to Identify Corona Virus

 Roche’s cobas SARS-CoV-2 Test Receives the US FDA’s Emergency Use Authorization to Identify Corona Virus

Roche’s cobas SARS-CoV-2 Test Receives the US FDA’s Emergency Use Authorization to Identify Corona Virus

Shots:

  • The US FDA has issued a EUA for Roche’s cobas SARS-CoV-2 test for the qualitative detection of SARS-CoV-2, in nasopharyngeal and oropharyngeal swab samples taken from patients who meet COVID-19 clinical/ epidemiological criteria for testing
  • The CE-IVD test is available in markets accepting the CE mark for patients with signs and symptoms of COVID-19. The CE mark and FDA’s EUA allow patients to access the diagnostic test to combat the disease
  • The cobas SARS-CoV-2 test can be run on Roche’s cobas 6800/ 8800 systems and provide results in 3.5hrs., offering operating efficiency & fastest time-to-results with the highest throughput providing ~96 results in ~3hrs. and a total of 1,440 results for the cobas 6800 system and 4,128 results for the cobas 8800 system in 24hrs.

Click here ­to­ read full press release/ article | Ref: Roche  | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post